Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6269MR)

This product GTTS-WQ6269MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6269MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12658MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ6205MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ11642MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ3941MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ179MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ14891MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ10801MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ13121MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW